申请人:Chen Ching-Shih
公开号:US20080269309A1
公开(公告)日:2008-10-30
Use of a new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of formula I for inducing apoptosis in unwanted rapidly proliferating cells, for treating, inhibiting, or delaying the onset of cancer, and for preventing restenosis in a subject that has undergone an angioplasty or stent:
wherein X is selected from the group consisting of alkyl and haloalkyl; Ar is an aryl radical selected from the group consisting of phenyl, biphenyl, naphthyl, anthryl, phenanthryl, and fluorenyl; and wherein Ar is optionally substituted with one or more radicals selected from the group consisting of halo, C
1
-C
4
alkyl, C
1
-C
4
haloalkyl, azido, C
1
-C
4
azidoalkyl, aryl, akylaryl, haloaryl, haloalkylaryl, and combinations thereof; and R is selected from the group consisting of nitrile, acetonitrile, ethylnitrile, propylnitrile, carboxamide, amidine, tetrazole, oxime, hydrazone, acetamidine, aminoacetamide, guanidine, and urea.
使用一种新的磷脂酰肌醇依赖性激酶-1(PDK-1)抑制剂(I式)用于诱导不需要的快速增殖细胞凋亡,用于治疗、抑制或延迟癌症发生,并用于预防经过血管成形术或支架的患者再狭窄:其中X选自烷基和卤代烷基的群体;Ar是选自苯基、联苯基、萘基、蒽基、菲基和芴基的芳基基团;其中Ar可选地被一个或多个选自卤素、C1-C4烷基、C1-C4卤代烷基、叠氮基、C1-C4叠氮基烷基、芳基、烷基芳基、卤代芳基、卤代烷基芳基和其组合的基团取代;R选自腈、乙腈、乙腈、丙腈、羧酰胺、胍、四唑、肟、酰肟、氨基乙酰胺、胍、尿素的群体。